In the third session from the Platelet Reactivity Testing Round Table, the panel discuss treatment options for high-risk PCI patients.

Among the many fascinating points discussed in this session are a number of key issues including (time of discussions within the video are listed in parenthesis):

1:10 – Evidence regarding antiplatelet drug response

3:45 – Treatment options for antiplatelet therapy in the cathlab

8:10 – Interpreting the finding of ARCTIC study

15:14 – Bleeding risk in patients with complex disease

17:40 – Is there a role for platelet function testing in assessing compliance?

18:30 – Value of platelet function testing for assessing whether there is a drug response

22:30 – Is the P2'i'12 assay robust enough to titrate a response?

The panel for this session comprises:

Robert Storey, Professor and Honorary Consultant in Cardiology, Department of Cardiovascular Science, University of Sheffield, UK (Chair)

Jean-Philippe Collet, Groupe Hospitalier Pitié-Salpêtrière, Paris, France

Antonio Colombo, San Raffaele Hospital, Milan, Italy

Jeff Dahlen, Chief Scientific Officer at Accumetrics, US

Radcliffe Cardiology and Interventional Cardiology Review extends its thanks to all panel members.